As of 2025-03-22, the Relative Valuation of Cogent Biosciences Inc (COGT) is (85.62) USD. This relative valuation is based on P/E multiples. With the latest stock price at 7.16 USD, the upside of Cogent Biosciences Inc based on Relative Valuation is -1295.9%.
The range of the Relative Valuation is (70.61) - (109.27) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 31.4x - 48.6x | 41.5x |
| Forward P/E multiples | 26.9x - 48.9x | 34.7x |
| Fair Price | (70.61) - (109.27) | (85.62) |
| Upside | -1086.2% - -1626.1% | -1295.9% |
| Date | P/E |
| 2025-03-18 | -3.23 |
| 2025-03-17 | -3.29 |
| 2025-03-14 | -3.18 |
| 2025-03-13 | -3.24 |
| 2025-03-12 | -3.38 |
| 2025-03-11 | -3.22 |
| 2025-03-10 | -3.05 |
| 2025-03-07 | -3.12 |
| 2025-03-06 | -3.30 |
| 2025-03-05 | -3.41 |
| 2025-03-04 | -3.19 |
| 2025-03-03 | -3.11 |
| 2025-02-28 | -3.35 |
| 2025-02-27 | -3.11 |
| 2025-02-26 | -2.99 |
| 2025-02-25 | -3.11 |
| 2025-02-24 | -3.32 |
| 2025-02-21 | -3.56 |
| 2025-02-20 | -3.60 |
| 2025-02-19 | -3.60 |
| 2025-02-18 | -3.60 |
| 2025-02-14 | -3.57 |
| 2025-02-13 | -3.64 |
| 2025-02-12 | -3.62 |
| 2025-02-11 | -3.75 |
| 2025-02-10 | -3.90 |
| 2025-02-07 | -3.89 |
| 2025-02-06 | -4.08 |
| 2025-02-05 | -4.30 |
| 2025-02-04 | -4.12 |
| 2025-02-03 | -4.00 |
| 2025-01-31 | -4.14 |
| 2025-01-30 | -4.28 |
| 2025-01-29 | -4.14 |
| 2025-01-28 | -3.97 |
| 2025-01-27 | -3.77 |
| 2025-01-24 | -3.72 |
| 2025-01-23 | -3.96 |
| 2025-01-22 | -3.65 |
| 2025-01-21 | -3.65 |
| 2025-01-17 | -3.57 |
| 2025-01-16 | -3.62 |
| 2025-01-15 | -3.61 |
| 2025-01-14 | -3.28 |
| 2025-01-13 | -3.37 |
| 2025-01-10 | -3.49 |
| 2025-01-08 | -3.61 |
| 2025-01-07 | -3.67 |
| 2025-01-06 | -3.59 |
| 2025-01-03 | -3.51 |